On June 12, the United States Supreme Court released a heavily anticipated decision relating to patent disputes between the developers of new biological medicines and the manufacturers of “biosimilar” copies of those medicines. This was the Court’s first
Read More...
Read the complete post at http://healthaffairs.org/blog/2017/06/19/sandoz-v-amgen-what-the-court-settled-what-it-didnt-and-what-might-come-next/
Posted
Jun 19 2017, 10:09 AM
by
Health Affairs BlogHealth Affairs Blog